Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though
the potential toxicities of the procedure remain high. We and others have shown that a less
toxic preparative regimen allows reliable allogeneic engraftment for allogeneic
transplantation.
The primary purpose of this treatment trial is to follow subjects undergoing allogeneic
transplantation for long term outcomes. The regimen used has been tested in our prior phase I
/ II trial which has completed accrual. The issues of engraftment and rate of graft versus
host disease have been answered and our success has led to this regimen being a standard
approach for less toxic allogeneic therapy.